chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Severe migraine; Medicine taste in back of throat; This is a spontaneous report from a contactable consumer, the patient. A 39-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8735) via an unspecified route of administration in the left arm on 25Apr2021 at 09:30 (at the age of 39-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had known allergy to bee venom. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included biotin (MANUFACTURER UNKNOWN), B-12 (MANUFACTURER UNKNOWN) and methadone (MANUFACTURER UNKNOWN); all for unspecified indication from unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. On 25Apr2021 at 10:30, the patient experienced severe migraine (all day, so far) and medicine taste in back of throat. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events migraine and medicine taste in back of throat was unknown at the time of this report.   No follow-up attempts are needed. No further information is expected.
2 family members died after getting vaccine; Initial information received on 08-Oct-2020 regarding an unsolicited valid serious social media case received from a consumer or non-healthcare professional via social media.  This case is linked to cases 2020SA282978 and 2020SA282955 (same reporter).  This case involves two patients who died after they received INFLUENZA VACCINE.  The patient's medical history, past medical treatment(s), vaccination(s), concomitant medications and family history were not provided.  On an unknown date, the patients received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer lot number and expiry date not reported via an unknown route in an unknown administration site for prophylactic vaccination.  On an unknown date, the reporter's family members died (death) unknown latency following the administration of INFLUENZA VACCINE. This event was assessed as medically significant.   Other relevant tests were not reported.  It was not reported if the patients received any corrective treatment before death.  It was unknown if an autopsy was done and cause of death was not reported.  There will be no information available on the batch number for this case.; Sender's Comments: This poorly documented social media case concerns two patients of unknown age who died after vaccination with INFLUENZA VACCINE (produced by unknown manufacture). The time to onset was unknown. However, patient's medical condition at the time of vaccination, autopsy result and lab tests ruling out alternate etiologies were not reported. Based on the limited information available, the role of the vaccine cannot be assessed.; Reported Cause(s) of Death: death
Face became deep red and very warm to touch.   No breathing problems; no dizziness or any other symptoms.
Significant dizziness started in the morning and continued for 2 weeks. Dizziness decreased in intensity but still present at the date of the report.
Covid arm - red, inflamed, circle on left arm  at injection site  3 inches in diameter, suddenly appearing  on day 8
SWELLING SORENESS AND VERY HOT. ARM SWELLED UP 2X IT'S SIZE TREATING WITH MOTRIN AND COLD COMPRESS WITH BENADRYL AND WE WILL RECHECK IN 2 DAYS UNLESS IT GETS WORSE
Approximately seven days after receiving my vaccine, I felt my heart started to flutter briefly. On 03/11/2021, I started feeling like my heart was racing. I sat down and checked my pulse and noticed it was over 100 as I was sitting down. I went to the ER. I was hooked up to a heart monitor, had blood drawn, received an IV and had an EKG. I was later diagnosed with AFIB. I was transported from the first location to the main hospital where I was admitted into the hospital. There I had an Echocardiogram done. I was released the next day. I had my medication, Amlodipine/Benazepril, switched to Lisinopril. I am now taking Diltiazem-Hydrochloride (which is for Arrhythmia) and Eliquis.
received dose two of Shingrix one month after dose one; This case was reported by a nurse via call center representative and described the occurrence of drug dose administration interval too short in a 56-year-old female patient who received Herpes zoster (Shingrix) (batch number AP545, expiry date 25th January 2023) for prophylaxis.   Concomitant products included Herpes zoster (Shingrix).   On 26th April 2021, the patient received the 2nd dose of Shingrix. On 26th April 2021, unknown after receiving Shingrix, the patient experienced drug dose administration interval too short. On an unknown date, the outcome of the drug dose administration interval too short was unknown.  Additional details were provided as follows: The reporter did not provide lot number or expiration date for dose one of Shingrix. The Patient received 2nd dose of Shingrix one month after dose one which led to shortening of vaccination schedule. The patient consented to follow up.
pt recvd vax & 1hr p/vax exp tingling of both hands @ top of head;addl felt like blood pressure was up;recovered p/2hrs;
Information has been received from the Merck Pregnancy Registry via a consumer concerning her 17 year old daughter with a food allergy to pineapples who on 05-APR-2007 received her first dose of Gardasil. Concomitant therapy included Phenergan. On 05-APR-2007, the patient experienced pain at the injection site for several hours. The patient sought unspecified medical attention. The patient recovered on 06-APR-2007. Subsequently, the patient was informed that she was pregnant by a physician at the hospital ER. Pregnancy was confirmed via pregnancy test. The date of her last menstrual period was approximately 15-MAR-2007 and her estimated delivery date is 20-DEC-2007. The patient was not admitted. Additional information has been requested.
No adverse event reported. Vaccine was reconstituted with bacteriostatic sodium chloride solution contrary to manufacturer's instructions.
loss of balance; gross hematuria; This case was reported by a consumer via other manufacturer and described the occurrence of loss of balance in a adult female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced loss of balance and hematuria. On an unknown date, the outcome of the loss of balance and hematuria were unknown.   It was unknown if the reporter considered the loss of balance and hematuria to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient experienced gross hematuria and loss of balance.
Fever of 100.7.  Chills.  Body aches.  Nausea.  Happened
Pt called with swelling in arm nearer to injection site. Said it was a hard lump and she had some pain. Today (5/25/18) pt calls and says she can move her arm and the hard swelling spot is gone. However, she says her arm is swelling (a soft swelling). She no longer has pain and can move her arm. She has been advised to take an anti-inflammatory. Also advised to contact her physician.
wheezing and cough approximately 48 hours post vaccine , also reports right arm has nerve pain down to hand and wrist (does have nerve damage in hand) and up to neck. Injection site mild pain and bruising. Took 2 25mg Benadryl and 2 200 mg ibuprofen at wheezing onset... took around 45 mins to stop the cough and an hour or so to stop wheeze. Nerve pain continues and fatigue but wheeze has ended.
Patient didn't receive the vaccine yet, passed more than 42 days of the time window between both doses. She was advised by her doctor to wait 12 weeks before receiving the second dose; Vaccine administered to pregnant; This spontaneous prospective pregnancy case was reported by a patient and describes the occurrence of OFF LABEL USE (Patient didn't receive the vaccine yet, passed more than 42 days of the time window between both doses. She was advised by her doctor to wait 12 weeks before receiving the second dose) and MATERNAL EXPOSURE DURING PREGNANCY (Vaccine administered to pregnant) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included COVID-19 in December 2020.    On 06-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. Last menstrual period and estimated date of delivery were not provided. On an unknown date, the patient experienced OFF LABEL USE (Patient didn't receive the vaccine yet, passed more than 42 days of the time window between both doses. She was advised by her doctor to wait 12 weeks before receiving the second dose) and MATERNAL EXPOSURE DURING PREGNANCY (Vaccine administered to pregnant). At the time of the report, OFF LABEL USE (Patient didn't receive the vaccine yet, passed more than 42 days of the time window between both doses. She was advised by her doctor to wait 12 weeks before receiving the second dose) outcome was unknown and MATERNAL EXPOSURE DURING PREGNANCY (Vaccine administered to pregnant) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No Concomitant medications were reported. No treatment medications were reported.   Reporter did not allow further contact   Most recent FOLLOW-UP information incorporated above includes: On 29-Jul-2021: Follow up added on 29-Jul-2021 and updated medical history and events.
Pt developed sensation of throat closing on leftside (Lt deltoid inj) slight hoarseness 10 min post vaccination with first Moderna dose. Epinephrine 0.3 at 8:10 Rt VL. Pt transported to ER for further evaluation VS 805 114/76-98% P75 VS 8:15 117/86 98% P86
Mother called 11/06 states that child had fever. 11/05 in late afternoon of 102.5(ear)- alternated Tylenol/Motrin. this am at 7 heard "banging"- child having seizure- "like one in 3/02" last 2-3 minutes. Then emesis- taken by ambulance to  hospital. Temp 101 (ear), 100.7 (ear) at ER. home at 10:30 playing active.
PATIENT COMPLAINING OF GENERALIZED JOINT/MUSCLE PAIN, NAUSEA BEGINNING ON 4/9/2021, PATIENT FAINTED ON 4/12/2021 AND HAS COMPLAINED OF LACK OF ENERGY AND INABILITY TO EVEN HAVE STRENGTH TO HOLD HER HEAD UP AS OF CURRENT DATE FROM DAY AFTER VACCINE ADMINISTERED
Soreness in arm, extreme body aches, headache, low-grade fever, fatigue, Swelling in left armpit
This is an instance of breakthrough COVID-19 after which death occurred. The individual was vaccinated with the Pfizer product on 01/28/2021 and 02/18/2021. They became symptomatic on approx 09/11/2021 with shortness of breath. They tested positive for COVID-19 on 09/16/2021, at the hospital. They were in palliative care at a care facility since May 2021. They died on 09/21/2021. I see an admit/discharge for the hospital indicated below for 09/08/2021-09/21/2021 but clinical notes dated 09/21/2021 indicate the induvial was receiving care at the care facility indicted in the address portion of this form on the day of their death (09/21/2021).
Local reaction at injection site. Redness, warm to touch. Itching. Pt had these symptoms for 5 days.
Shot given at 10:30 am, lunch of sandwich at 11:00 am.  1:00 pm feel moderately dizzy.  No other symptoms at this time. No treatment given.  Will call doctor if symptoms increase or last more than a few hours.
Pt vaccinated at 12:30 with COVID-19 Moderna, 1st dose. While waiting in her car at the observation station of the drive-thru site, pt began to feel like her heart rate was up. Alert and talking, no distress noted. VS  Pulse 95 bpm, Respirations 16 per minute, O2 sat 99% and BP 142/98.  Random blood glucose 93. Pt given ice pack to apply to neck. Pt reported hx of panic attacks and fainting in the past. Staff stayed with pt until she felt better. Pt was discharged to home via her own car she was driving at 1:15 PM.
pt recv vax & devel an inj site rxn pain & a weird feeling in arm;addtl info was recv 31JUL96;pt recovered;
p/vax pt devel a fever of 99.6 & was seen by MD;pt hosp w/dx of fever of unk origin;max temp while in hosp was 100.9;pt recovered & was discharged on 6/20/99;
states began feeling ill 23OCT93; states on 24-25OCT was out of head, could not eat, got the the bathroom but admit to urinating some; began coughing up phelgm; states wife said pt was covered w/ red blotches;
Side effects were flu-like symptoms (fever/chills) and horrible joint pains, severe headache, body aches which I reported to my Primary Physician - Dr. - she advised me to not take the 2nd shot
This spontaneous report as received from a healthcare worker refers to a 70 year old patient of unknown gender and demographics. Patient's current condition and medical history was not reported. On 15-SEP-2014, the patient was vaccinated with ZOSTAVAX subcutaneous injection, 0.65 ml, lot # J005721 expiration date: 29-AUG-2014 for an unknown indication. No concomitant medication was reported. On 15-SEP-2014, the patient received an expired dose of ZOSTAVAX intramuscularly in the left deltoid after having transported the dose of ZOSTAVAX from the pharmacy to the physician's office. On 15-SEP-2014, the dose was exposed to an unknown temperature during transport by the patient. On an unknown date in September 2014, no adverse effect was observed or reported by the patient. There was no product quality complaint involved. The outcome of the events was not reported. The causality between ZOSTAVAX and the events was not reported. Additional information has been requested.
the patients viral load was 20 in January, 116 in March, Increased viral load to 368; This non-serious case was reported by a other health professional via call center representative and described the occurrence of viral load increased in a adult male patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included cabotegravir, rilpivirine (Cabenuva) suspension for injection for product used for unknown indication.   Previously administered products included Triumeq (The patient had received Dovato and Triumeq (historical drugs) prior to starting Cabenuva) and Dovato.   In APR-2023, the patient received Shingrix. In JAN-2023, the patient started Cabenuva. In APR-2023, less than a month after receiving Shingrix and between 2 and 4 months after starting Cabenuva, the patient experienced viral load increased (Verbatim: the patients viral load was 20 in January, 116 in March, Increased viral load to 368). The action taken with Cabenuva was unknown. The outcome of the viral load increased was unknown.   It was unknown if the reporter considered the viral load increased to be related to Shingrix, Cabenuva, Cabenuva Needle Device, Cabenuva Syringe Device and Cabenuva Vial Adaptor Device.     It was unknown if the company considered the viral load increased to be related to Shingrix, Cabenuva, Cabenuva Needle Device, Cabenuva Syringe Device and Cabenuva Vial Adaptor Device.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 09-MAY-2023  Manager called on behalf of an healthcare professional (Case Manager).   The patient received the first dose of Cabenuva (600/900) in January, the second dose in February and the third dose on 27th April 2023.  The patient also received Shingrix 2 weeks prior to receiving the third dose of Cabenuva.  The viral load had increased to 368 just prior to the third dose of Cabenuva, the patient's viral load was 20 in January and 116 in March. The reporter did not consent to follow-up.
pt exp pruritus, erythema, swelling, & warmth @ inject site p/recvd flu vax; 3 days, swelling had incr to cover an area of 10 cm; rxn resolved p/1 & 1/2 wks;
This spontaneous report as received from a healthcare worker (medical assistant) refers to a patient of unknown age and gender. Information regarding relevant medical history and concurrent condition were not reported. On 15-MAR-2016 the patient was vaccinated with RECOMBIVAX HB (dose 3, lot # L025838, expiration date 14-AUG-2017, 5 microgram/0.5 ml injection, dose 5 microgram, intramuscular). On the same day, the reporter also administered PEDIARIX (dose, route and lot # not reported) to the patient. No adverse effects were reported. Additional information has been requested.
subjective feeling of weakness tingling of anterior leg thigh and dorsa of foot  pain in thighs
Pt. states that after receiving the 2nd dose of Moderna 08/17/2021, started experiencing symptoms 08/18/2021 of pain throughout the body, weakness, headaches, and blurry vision. Primary visit planned 08/19/2021.
Initial report received from a consumer on 08 September 2008. A 43-year-old female patient with a medical history of migraines, "heart infection", IgA deficiency and "weariness episodes" had stepped on a nail on 17 August 2008. On 24 August 2008, the patient experienced "jaw tightening" and went to the emergency room where she received a dose of Tetanus Toxoid Adsorbed (lot number and route/site of administration unknown). On 26 August 2008, the patient experienced a "horrible feeling of doom" and went to the emergency room (treatment was not reported) and was sent home. On 03 September 2008, the patient developed dizziness, shakiness, nausea, went limp and fell out of the car. She again went to the emergency room (treatment not reported) and was released. On 04 September 2008, the patient experienced the same symptoms as the day before, went to the emergency room and was again released. On 07 September 2008, the patient went limp and fell to the ground. She was taken to the emergency room and was held overnight. The patient reported that an EEG and "MI tests" were negative. Patient outcome was reported to be unknown.
I got the shots for shingles, still had shingles/suspected vaccination failure; had shingles; sick and meds they made me sick; This case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant), shingles and sickness. On an unknown date, the outcome of the vaccination failure, shingles and sickness were unknown.   It was unknown if the reporter considered the vaccination failure, shingles and sickness to be related to Shingles vaccine.   Additional Information: GSK receipt date: 27-MAR-2022 Reporter's comment: This case was reported via interactive digital media. The patient got the shots for shingles but still had shingles and was so sick.  The physician gave him/her medicine and they made him/her sick so the patient let shingles run its purse.  Additional supportive information: The case was reported by the patient. This case was considered as suspected vaccination failure as details regarding completion of primary vaccination schedule, time to onset and laboratory test confirming shingles were unknown at the time of reporting. The follow up would not possible as no contact details were available.
I had a violent reaction to my high-dose flu shot last thurs 3pm. By around 9pm, uncontrollable shaking, skin hurt, wherever I have arthritis became enflamed.  I started taking Advil but even with that I had temp of 101 but became normal the next day. The worst was that it triggered my pericarditis very badly - the worst in many, many years. So painful I had to sleep sitting up.  I have been treating with Advil and much, much better. Flu symptoms now gone.
Employee states that flu vaccine was given on the morning of Wednesday 10/12, with no adverse event.  On the evening of Friday, 10/14, she experienced an unwitnessed seizure. She reported this event to Health dept. on Tuesday 10/18.
Body aches, joint aches, teeth aching  the day of shot.  Diarrhea Since receiving  the vaccine. Sore right arm for one day.
VARIVAX underwent a temperature excursion and was administered; This spontaneous report as received from a licensed practical nurse refers to a patient of unknown age and gender. On 18-JUN-2021, the patient was vaccinated with a dose of varicella virus vaccine live (Oka/Merck) (VARIVAX) (lot # T029533 exp date 01-SEP-2022) (dose and route not reported) that underwent a temperature excursion. Previous temperature of excursion was 6°F to 14°F (14F) for 2 hours, 14°F to 46°F (45.5F) 1 hour and 30 minutes and 6°F t o14°F (14.4F) for 2 hours.  This is one of several reports received from the same source.; Sender's Comments:  US-009507513-2106USA006458: US-009507513-2106USA006460: US-009507513-2106USA006461: US-009507513-2106USA006462: US-009507513-2106USA006463: US-009507513-2106USA006464: US-009507513-2106USA006465: US-009507513-2106USA006466: US-009507513-2106USA006467: US-009507513-2106USA006468: US-009507513-2106USA006469: US-009507513-2106USA006470: US-009507513-2106USA006471: US-009507513-2106USA006472: US-009507513-2106USA006473: US-009507513-2106USA006474: US-009507513-2106USA006475: US-009507513-2106USA006476: US-009507513-2106USA006477: US-009507513-2106USA006478: US-009507513-2106USA006479: US-009507513-2106USA006480: US-009507513-2106USA006481: US-009507513-2106USA006482: US-009507513-2106USA006483: US-009507513-2106USA006484: US-009507513-2106USA006485: US-009507513-2106USA006486: US-009507513-2106USA006487: US-009507513-2106USA006488: US-009507513-2106USA006489: US-009507513-2106USA006490: US-009507513-2106USA006491: US-009507513-2106USA006492: US-009507513-2106USA006493: US-009507513-2106USA006494: US-009507513-2106USA006495: US-009507513-2106USA006496: US-009507513-2106USA006497: US-009507513-2106USA006498:
Patient presented to the ED on 08/05 with 2 month history of progressive neurological symptoms that included, headache, double vision, extremity weakness, tremors.